

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/12263

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :G01N 33/483, 35/00

US CL : 436/46, 63

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 436/46, 63

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

U.S. PTO Scientific and Technical Information Center Library Catalog

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 3,431,886 A (MCCORMICK et al.) 03 March 1969, entire document.	1, 3, and 4
Y	US 5,650,327 A (COPELAND et al.) 22 July 1997, entire document and especially column 1, lines 10-20, and column 4, lines 35-50.	1-5
Y	MCMANNUS et al. Staining Methods Histologic and Histochemical, Paul B. Hoeber, Inc., New York, September 1960, pages 124-151, 223-245, and 361-372, especially pages 134, 138, 149, 228, 240, and 368.	3-9

 Further documents are listed in the continuation of Box C. See patent family annex.

•	Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A"	document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E"	earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O"	document referring to an oral disclosure, use, exhibition or other means		
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

18 AUGUST 1999

Date of mailing of the international search report

10 SEP 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer
BRENDA BRUMBACK
R. Lawrence Far

Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US99/12263

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, DIALOG: Medline, BIOTECH, Conf. Papers, Euro, Japio
search terms: histologic, histology, cytologic, cytology, stain, automate(d), tissue, cell, smear, silver stain, methanamine, borax, ammonium hydroxide, hematoxylin, eosin, potassium ferrocyanate, ferric chloride, mucicarmine, trichrome, verhoff, amyloid, steiner

PATENT COOPERATION TREATY

OCKETED

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

NOV 06 2000

To: AMIR N. PENN
MCDONNELL BOEHNEN HULBERT & BERGHOFF
300 SOUTH WACKER DRIVE
CHICAGO, ILLINOIS 60606

PCT

DUE DATE:

BY:

~~SBF~~NOTIFICATION OF TRANSMITTAL OF
INTERNATIONAL PRELIMINARY
EXAMINATION REPORT

(PCT Rule 71.1)

Date of Mailing
(day/month/year)

01 NOV 2000

Applicant's or agent's file reference

98,375-A

IMPORTANT NOTIFICATION

International application No.	International filing date (day/month/year)	Priority Date (day/month/year)
PCT/US99/12263	02 JUNE 1999	02 JUNE 1998

Applicant

VENTANA MEDICAL SYSTEMS, INC.

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.

4. REMINDER

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau via PCT/IB/11).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer
BRENDA BRUMBACK

Telephone No. (703) 308-0196

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 98,375-A	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US99/12263	International filing date (day/month/year) 02 JUNE 1999	Priority date (day/month/year) 02 JUNE 1998
International Patent Classification (IPC) or national classification and IPC IPC(7): G01N 33/483, 35/00 and US Cl.: 436/46, 63		
Applicant VENTANA MEDICAL SYSTEMS, INC.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 4 sheets.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 3 sheets.

3. This report contains indications relating to the following items:

- I Basis of the report
- II Priority
- III Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV Lack of unity of invention
- V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI Certain documents cited
- VII Certain defects in the international application
- VIII Certain observations on the international application

Date of submission of the demand 28 DECEMBER 1999	Date of completion of this report 21 SEPTEMBER 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer  BRENDA BRUMBACK Telephone No. (703) 308-0196

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/12263

I. Basis of the report

1. With regard to the elements of the international application:*

 the international application as originally filed the description:

pages _____ (See Attached) _____, as originally filed

pages _____, filed with the demand

pages _____, filed with the letter of _____

 the claims:

pages _____ (See Attached) _____, as originally filed

pages _____, as amended (together with any statement) under Article 19

pages _____, filed with the demand

pages _____, filed with the letter of _____

 the drawings:

pages _____ (See Attached) _____, as originally filed

pages _____, filed with the demand

pages _____, filed with the letter of _____

 the sequence listing part of the description:

pages _____ (See Attached) _____, as originally filed

pages _____, filed with the demand

pages _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language _____ which is:

 the language of a translation furnished for the purposes of international search (under Rule 23.1(b)). the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

 contained in the international application in printed form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.4. The amendments have resulted in the cancellation of: the description, pages _____ NONE the claims, Nos. _____ NONE the drawings, sheets/fig. _____ NONE5. This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. statement

Novelty (N)	Claims <u>1-9</u>	YES
	Claims <u>NONE</u>	NO
Inventive Step (IS)	Claims <u>NONE</u>	YES
	Claims <u>1-9</u>	NO
Industrial Applicability (IA)	Claims <u>1-9</u>	YES
	Claims <u>NONE</u>	NO

2. citations and explanations (Rule 70.7)

Claims 1-9 lack an inventive step under PCT Article 33(3) as being obvious over McCormick et al. in view of Copeland et al. and McMannus et al.

McCormick et al. teach an automated method for staining biological materials on a slide comprising providing a plurality of staining solutions (see column 2, lines 6-17), providing a slide having biological material such as cells or tissue sections placed thereon (see column 1, lines 36-45), providing an automated delivery system to deliver a predetermined amount of the staining solutions to the slide, and sequentially applying the staining solutions to the slide (see column 2, lines 18-40).

Copeland et al. teach an automated method for staining tissue sections mounted on slides (see column 1, lines 15-20) comprising applying an aqueous reagent staining solution to the slide and mixing the solution on the surface of the slide containing the tissue by applying a gas stream to the aqueous reagent directly on the slide (see column 4, lines 28-50).

McMannus et al. teach standard staining solutions for histologic staining of tissue sections and fungi, as iron stain with potassium ferrocyanide and hydrochloric acid (page 134), mucicarmine (page 138), amyloid stain (page 149), silver stain with silver nitrate, sodium hydroxide and ammonia (page 228), Verhoeff's stain with hematoxylin and ferric chloride (see page 240), and silver stain with methenamine and borax. McMannus et al. teach mixing the working solutions of the stains just prior to use from stable stock reagents because the working solutions themselves are unstable for storage over time (see page 134, #2; page 135, #4; page 138, #2; page 240, "Verhoeff's Elastic Tissue Stain, first paragraph; and page 368, last line of the page).

Because McCormick et al. teach an automated staining method for staining biological materials on a slide comprising sequential application of staining solutions, Copeland et al. teach automated mixing of staining solutions on the slide, and McMannus et al. teach the claimed staining solutions and teach mixing the staining solutions just prior to use, the claimed method cannot be considered as having required an inventive step.

(Continued on Supplemental Sheet.)

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

I. BASIS OF REPORT:

This report has been drawn on the basis of the description,
page(s) 1-21, as originally filed.

page(s) NONE, filed with the demand.

and additional amendments:

NONE

This report has been drawn on the basis of the claims,
page(s) NONE, as originally filed.

page(s) NONE, as amended under Article 19.

page(s) NONE, filed with the demand.

and additional amendments:

Claim PAGES 22-24, filed with the letter of 21 August 2000.

This report has been drawn on the basis of the drawings,
page(s) NONE, as originally filed.

page(s) NONE, filed with the demand.

and additional amendments:

NONE

This report has been drawn on the basis of the sequence listing part of the description:

page(s) NONE, as originally filed.

page(s) NONE, filed with the demand.

and additional amendments:

NONE

5. (Some) amendments are considered to go beyond the disclosure as filed:

NONE

V. 2. REASoNED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):

Applicant has submitted arguments regarding the determination that claims 1-9 lack an inventive step under PCT Article 33(3) as being obvious over McCormick et al. in view of Copeland et al. and McMannus et al. Applicant's arguments have been fully considered but they are not persuasive. Applicant argues that the staining methods taught by McMannus et al. first require mixing of the stable solutions and then dispensing of the combined or working solution, whereas the staining methods of the claimed invention combine an automated delivery system with sequential dispensing the stable solutions and mixing the working solutions on the slide. Applicant is arguing against the McMannus et al. reference individually, whereas the determination was based on a combination of references. The McMannus et al. reference is but one of the secondary references. The teaching of the automated system and sequential application of staining solutions is found in McCormick et al. and the teaching of mixing the solution on the surface of the slide is found in Copeland et al. Therefore, all elements of the claimed method are taught in the prior art and claims 1-9 cannot be considered to have required an inventive step.

----- NEW CITATIONS -----

NONE

We claim:

1. An automated method for staining biological materials on a slide,

comprising:

- a) providing at least a first and second stable solution, wherein the at least first and second stable solutions when combined comprise an unstable staining solution;
- b) providing a slide, wherein a biological material to be stained is present on the slide;
- c) providing an automated delivery system to deliver a predetermined quantity of the at least first and second stable solutions to the biological material on the slide;
- d) sequentially applying the at least first and second stable solutions to the biological material on the slide using the automated delivery system; and
- e) mixing the at least first and second stable solutions on the biological material.

2. The method of claim 1 wherein the step of mixing includes applying at least two gas streams to form a vortex.

3. The method of claim 1 wherein said biological material is selected from the group consisting of tissue sections, tissue culture cells, cell components, including cell organelles, chromosomes, nucleic acids, carbohydrates, lipids, and proteins, smears of blood, sputum, and other body fluids, excretions and secretions, and micro-organisms including parasites, viruses, bacteria, and fungi.

4. The method of claim 1 wherein said unstable staining solution is selected from the group consisting of fungi staining solutions, silver staining solutions, iron staining solutions, iron hematoxylin solutions, trichrome staining solutions, mucin stains, mucicarmine staining solutions, Verhoff's staining solution, amyloid staining solutions, and Steiner staining solution.

5. The method of claim 1 wherein the mixing is accomplished by applying a gas stream to the at least first and second stable solutions on the biological material.

30 6. An automated method for silver staining biological materials on a slide, comprising:

a) providing a solution of from about 0.2% to about 1.0% silver nitrate, wherein the silver nitrate is at least first and second stable solutions when combined comprise an unstable staining solution;

5 b) providing a solution of from about 2.0% to about 4.0% methenamine

c) providing a solution of from about 0.2% to about 0.6% borax

d) providing a slide, wherein a biological material to be stained is present on the horizontal slide;

10 e) providing an automated delivery system to deliver a predetermined quantity of the silver nitrate, methenamine, and borax solutions to the biological material on the slide;

f) sequentially applying the silver nitrate, methenamine, and borax solutions to the biological material on the slide using the automated delivery system; and

15 g) mixing the silver nitrate, methenamine, and borax solutions to stain the biological material.

7. An automated method for silver staining biological materials on a slide, comprising:

a) providing a solution of from about 0.2% to about 1.0% silver nitrate;

b) providing a solution of from about 0.3% to about 1.0% ammonium

20 hydroxide

c) providing a solution of from about 0.7% to about 1.5% sodium hydroxide

d) providing a slide, wherein a biological material to be stained is present on the slide;

25 e) providing an automated delivery system to deliver a predetermined quantity of the silver nitrate, ammonium hydroxide, and sodium hydroxide solutions to the biological material on the slide;

f) sequentially applying the silver nitrate, ammonium hydroxide, and sodium hydroxide solutions to the biological material on the slide using the automated delivery system; and

30 g) mixing the silver nitrate, ammonium hydroxide, and sodium hydroxide solutions to stain the biological material.

8. An automated method for trichrome or mucicarmine staining of biological materials on a slide, comprising:

- a) providing a solution of from about 0.7% to about 1.5% hematoxylin;
- b) providing a solution of from about 0.5% to about 1.5% aqueous ferric chloride;
- c) providing a slide, wherein a biological material to be stained is present on the slide;
- d) providing an automated delivery system to deliver a predetermined quantity of the hematoxylin and aqueous ferric chloride solutions to the biological material on the slide;
- e) sequentially applying the hematoxylin and aqueous ferric chloride solutions to the biological material on the slide using the automated delivery system; and
- f) mixing the hematoxylin and aqueous ferric chloride solutions to stain the biological material.

9. An automated method for iron staining of biological materials on a slide, comprising:

- a) providing a solution of from about 8% to about 12% potassium ferrocyanate;
- b) providing a solution of from about 15% to about 30% hydrochloric acid;
- c) providing a slide, wherein a biological material to be stained is present on the slide;
- d) providing an automated delivery system to deliver a predetermined quantity of the potassium ferrocyanate and hydrochloric acid solutions to the biological material on the slide;
- e) sequentially applying the hematoxylin and aqueous ferric chloride solutions to the biological material on the slide using the automated delivery system; and
- f) mixing the potassium ferrocyanate and hydrochloric acid solutions to stain the biological material.

PATENT COOPERATION TREATY

PCT

REC'D 06 NOV 2000

WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 98,375-A	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. PCT/US99/12263	International filing date (day/month/year) 02 JUNE 1999	Priority date (day/month/year) 02 JUNE 1998
International Patent Classification (IPC) or national classification and IPC IPC(7): G01N 33/483, 35/00 and US Cl.: 436/46, 63		
Applicant VENTANA MEDICAL SYSTEMS, INC.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 4 sheets.

This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of 3 sheets.

3. This report contains indications relating to the following items:

- I Basis of the report
- II Priority
- III Non-establishment of report with regard to novelty, inventive step or industrial applicability
- IV Lack of unity of invention
- V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI Certain documents cited
- VII Certain defects in the international application
- VIII Certain observations on the international application

Date of submission of the demand 28 DECEMBER 1999	Date of completion of this report 21 SEPTEMBER 2000
Name and mailing address of the IPEA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized officer  BRENDA BRUMBACK Telephone No. (703) 308-0196

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US99/12263

I. Basis of the report

1. With regard to the elements of the international application:*

 the international application as originally filed the description:

pages _____ (See Attached) _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

 the claims:

pages _____ (See Attached) _____, as originally filed
 pages _____, as amended (together with any statement) under Article 19
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

 the drawings:

pages _____ (See Attached) _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

 the sequence listing part of the description:

pages _____ (See Attached) _____, as originally filed
 pages _____, filed with the demand
 pages _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language _____ which is:

 the language of a translation furnished for the purposes of international search (under Rule 23.1(b)). the language of publication of the international application (under Rule 48.3(b)). the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

 contained in the international application in printed form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished. The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.4. The amendments have resulted in the cancellation of: the description, pages _____ NONE the claims, Nos. _____ NONE the drawings, sheets/fig. _____ NONE5. This report has been drawn as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

**Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. statement

Novelty (N)	Claims	<u>1-9</u>	YES
	Claims	<u>NONE</u>	NO
Inventive Step (IS)	Claims	<u>NONE</u>	YES
	Claims	<u>1-9</u>	NO
Industrial Applicability (IA)	Claims	<u>1-9</u>	YES
	Claims	<u>NONE</u>	NO

2. citations and explanations (Rule 70.7)

Claims 1-9 lack an inventive step under PCT Article 33(3) as being obvious over McCormick et al. in view of Copeland et al. and McMannus et al.

McCormick et al. teach an automated method for staining biological materials on a slide comprising providing a plurality of staining solutions (see column 2, lines 6-17), providing a slide having biological material such as cells or tissue sections placed thereon (see column 1, lines 36-45), providing an automated delivery system to deliver a predetermined amount of the staining solutions to the slide, and sequentially applying the staining solutions to the slide (see column 2, lines 18-40).

Copeland et al. teach an automated method for staining tissue sections mounted on slides (see column 1, lines 15-20) comprising applying an aqueous reagent staining solution to the slide and mixing the solution on the surface of the slide containing the tissue by applying a gas stream to the aqueous reagent directly on the slide (see column 4, lines 28-50).

McMannus et al. teach standard staining solutions for histologic staining of tissue sections and fungi, as iron stain with potassium ferrocyanide and hydrochloric acid (page 134), mucicarmine (page 138), amyloid stain (page 149), silver stain with silver nitrate, sodium hydroxide and ammonia (page 228), Verhoeff's stain with hematoxylin and ferric chloride (see page 240), and silver stain with methenamine and borax. McMannus et al. teach mixing the working solutions of the stains just prior to use from stable stock reagents because the working solutions themselves are unstable for storage over time (see page 134, #2; page 135, #4; page 138, #2; page 240, "Verhoeff's Elastic Tissue Stain, first paragraph; and page 368, last line of the page).

Because McCormick et al. teach an automated staining method for staining biological materials on a slide comprising sequential application of staining solutions, Copeland et al. teach automated mixing of staining solutions on the slide, and McMannus et al. teach the claimed staining solutions and teach mixing the staining solutions just prior to use, the claimed method cannot be considered as having required an inventive step.

(Continued on Supplemental Sheet.)

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of: Boxes I - VIII

Sheet 10

I. BASIS OF REPORT:

This report has been drawn on the basis of the description,
page(s) 1-21, as originally filed.
page(s) NONE , filed with the demand.
and additional amendments:
NONE

This report has been drawn on the basis of the claims,
page(s) NONE, as originally filed.
page(s) NONE, as amended under Article 19.
page(s) NONE, filed with the demand.
and additional amendments:
Claim PAGES 22-24, filed with the letter of 21 August 2000.

This report has been drawn on the basis of the drawings,
page(s) NONE, as originally filed.
page(s) NONE , filed with the demand.
and additional amendments:
NONE

This report has been drawn on the basis of the sequence listing part of the description:
page(s) NONE, as originally filed.
pages(s) NONE, filed with the demand.
and additional amendments:
NONE

5. (Some) amendments are considered to go beyond the disclosure as filed:
NONE

V. 2. REASONED STATEMENTS - CITATIONS AND EXPLANATIONS (Continued):

Applicant has submitted arguments regarding the determination that claims 1-9 lack an inventive step under PCT Article 33(3) as being obvious over McCormick et al. in view of Copeland et al. and McMannus et al. Applicant's arguments have been fully considered but they are not persuasive. Applicant argues that the staining methods taught by McMannus et al. first require mixing of the stable solutions and then dispensing of the combined or working solution, whereas the staining methods of the claimed invention combine an automated delivery system with sequential dispensing the stable solutions and mixing the working solutions on the slide. Applicant is arguing against the McMannus et al. reference individually, whereas the determination was based on a combination of references. The McMannus et al. reference is but one of the secondary references. The teaching of the automated system and sequential application of staining solutions is found in McCormick et al. and the teaching of mixing the solution on the surface of the slide is found in Copeland et al. Therefore, all elements of the claimed method are taught in the prior art and claims 1-9 cannot be considered to have required an inventive step.

----- NEW CITATIONS -----

NONE

RECEIVED
ART 34 ANDT

We claim:

1. An automated method for staining biological materials on a slide, comprising:
 - a) providing at least a first and second stable solution, wherein the at least first and second stable solutions when combined comprise an unstable staining solution;
 - b) providing a slide, wherein a biological material to be stained is present on the slide;
 - c) providing an automated delivery system to deliver a predetermined quantity of the at least first and second stable solutions to the biological material on the slide; and
 - d) sequentially applying the at least first and second stable solutions to the biological material on the slide using the automated delivery system.
2. The method of claim 1 further comprising mixing the at least first and second stable solutions on the biological material.
3. The method of claim 1 wherein said biological material is selected from the group consisting of tissue sections, tissue culture cells, cell components, including cell organelles, chromosomes, nucleic acids, carbohydrates, lipids, and proteins, smears of blood, sputum, and other body fluids, excretions and secretions, and micro-organisms including parasites, viruses, bacteria, and fungi.
4. The method of claim 1 wherein said unstable staining solution is selected from the group consisting of fungi staining solutions, silver staining solutions, iron staining solutions, iron hematoxylin solutions, trichrome staining solutions, mucin stains, mucicarmine staining solutions, Verhoff's staining solution, amyloid staining solutions, and Steiner staining solution.
5. The method of claim 2 wherein the mixing is accomplished by applying a gas stream to the at least first and second stable solutions on the biological material.
6. An automated method for silver staining biological materials on a slide, comprising:
 - a) providing a solution of from about 0.2% to about 1.0% silver nitrate, wherein the silver nitrate is at least first and second stable solutions when combined comprise an unstable staining solution;

- b) providing a solution of from about 2.0% to about 4.0% methenamine
- c) providing a solution of from about 0.2% to about 0.6% borax
- d) providing a slide, wherein a biological material to be stained is present on the horizontal slide;

5 e) providing an automated delivery system to deliver a predetermined quantity of the silver nitrate, methenamine, and borax solutions to the biological material on the slide;

- f) sequentially applying the silver nitrate, methenamine, and borax solutions to the biological material on the slide using the automated delivery system;

10 and

- g) mixing the silver nitrate, methenamine, and borax solutions to stain the biological material.

7. An automated method for silver staining biological materials on a slide, comprising:

- 15 a) providing a solution of from about 0.2% to about 1.0% silver nitrate;
- b) providing a solution of from about 0.3% to about 1.0% ammonium hydroxide
- c) providing a solution of from about 0.7% to about 1.5% sodium hydroxide
- 20 d) providing a slide, wherein a biological material to be stained is present on the slide;
- e) providing an automated delivery system to deliver a predetermined quantity of the silver nitrate, ammonium hydroxide, and sodium hydroxide solutions to the biological material on the slide;
- 25 f) sequentially applying the silver nitrate, ammonium hydroxide, and sodium hydroxide solutions to the biological material on the slide using the automated delivery system; and
- g) mixing the silver nitrate, ammonium hydroxide, and sodium hydroxide solutions to stain the biological material.

30 8. An automated method for trichrome or mucicarmine staining of biological materials on a slide, comprising:

- a) providing a solution of from about 0.7% to about 1.5% hematoxylin;

- b) providing a solution of from about 0.5% to about 1.5% aqueous ferric chloride
- c) providing a slide, wherein a biological material to be stained is present on the slide;
- 5 d) providing an automated delivery system to deliver a predetermined quantity of the hematoxylin and aqueous ferric chloride solutions to the biological material on the slide;
- e) sequentially applying the hematoxylin and aqueous ferric chloride solutions to the biological material on the slide using the automated delivery system;
- 10 and
- f) mixing the hematoxylin and aqueous ferric chloride solutions to stain the biological material.

9. An automated method for iron staining of biological materials on a slide, comprising:

- 15 a) providing a solution of from about 8% to about 12% potassium ferrocyanate;
- b) providing a solution of from about 15% to about 30% hydrochloric acid
- c) providing a slide, wherein a biological material to be stained is present on the slide;
- 20 d) providing an automated delivery system to deliver a predetermined quantity of the potassium ferrocyanate and hydrochloric acid solutions to the biological material on the slide;
- e) sequentially applying the hematoxylin and aqueous ferric chloride solutions to the biological material on the slide using the automated delivery system;
- 25 and
- f) mixing the potassium ferrocyanate and hydrochloric acid solutions to stain the biological material.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : G01N 33/483, 35/00		A1	(11) International Publication Number: WO 99/63342 (43) International Publication Date: 9 December 1999 (09.12.99)
(21) International Application Number: PCT/US99/12263 (22) International Filing Date: 2 June 1999 (02.06.99)		(81) Designated States: JP, US, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).	
(30) Priority Data: 60/087,673 2 June 1998 (02.06.98) US		Published <i>With international search report.</i>	
(71) Applicant (for all designated States except US): VENTANA MEDICAL SYSTEMS, INC. [US/US]; 3865 North Business Center Drive, Tucson, AZ 85705 (US).			
(72) Inventors; and (75) Inventors/Applicants (for US only): <u>MEHTA</u> , Parula [US/US]; 7374 N. Mona Lisa Road #10103, Tucson, AZ 85741 (US). <u>GRAHAM</u> , Marshal [US/US]; 4858 East Winsett Street, Tucson, AZ 85711 (US). <u>POMERANTZ</u> , Anlouise [US/US]; 4656 El Camino de Cerro, Tucson, AZ 85705 (US).			
(74) Agent: HARPER, David, S.; McDonnell Boehnen Hulbert & Berghoff, 300 South Wacker Drive, Chicago, IL 60606 (US).			
(54) Title: METHOD FOR STAINING BIOLOGICAL SPECIMENS BY COMBINING UNSTABLE REAGENTS ON A MICROSCOPE SLIDE			
(57) Abstract <p>The present invention relates to automated methods for staining biological materials on a slide comprising the use of component histochemical solutions mixed directly on a biological sample of interest. The method comprises providing at least two stable solutions that together comprise an unstable staining solution, sequentially delivering the stable solutions to a biological sample of interest on a surface, and mixing the stable solutions directly on the biological material of interest to effectuate staining of the material.</p>			

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/12263

A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :G01N 33/483, 35/00

US CL : 436/46, 63

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 436/46, 63

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

U.S. PTO Scientific and Technical Information Center Library Catalog

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 3,431,886 A (MCCORMICK et al.) 03 March 1969, entire document.	1, 3, and 4
Y	US 5,650,327 A (COPELAND et al.) 22 July 1997, entire document and especially column 1, lines 10-20, and column 4, lines 35-50.	1-5
Y	MCMANNUS et al. Staining Methods Histologic and Histochemical, Paul B. Hoeber, Inc., New York, September 1960, pages 124-151, 223-245, and 361-372, especially pages 134, 138, 149, 228, 240, and 368.	3-9

 Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
A document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
E earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
O document referring to an oral disclosure, use, exhibition or other means		
P document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search
18 AUGUST 1999

Date of mailing of the international search report

10 SEP 1999

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231
Facsimile No. (703) 305-3230Authorized officer
Brenda Brumback
BRENDA BRUMBACK
Telephone No. (703) 308-0196

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US99/12263

B. FIELDS SEARCHED

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, DIALOG: Medline, BIOTECH, Conf. Papers, Euro, Japio
search terms: histologic, histology, cytologic, cytology, stain, automate(d), tissue, cell, smear, silver stain, methanamine, borax, ammonium hydroxide, hematoxylin, eosin, potassium ferrocyanate, ferric chloride, mucicarmine, trichrome, verhoff, amyloid, steiner

MBHB Case No. 98,375-A

Method for Staining Biological Specimens by Combining Unstable Reagents on a Microscope Slide

5

Related Applications

This application is a continuation in part of U.S. Application Serial No. 60/087,673 filed June 2, 1998.

10

Field of the Invention

The present invention relates to formulations for component histochemical staining solutions as well as methods for formulating, storing, and combining components of unstable histochemical staining solutions. In particular, the present invention relates to methods for combining component histochemical solutions directly on the biological sample of interest.

Background

20 Histochemistry is the science by which chemical reactions are used to identify particular substances within a cell. One method of identifying particular substances in the cell is by staining the cells with chemicals (dyes) that make such substances or structures more visible. Perhaps the most common stain materials are hematoxylin and eosin. Hematoxylin is utilized to stain the nuclei of the cell dark blue while eosin stains the cell cytoplasm various shades of red or yellow that contrast with the blue stain of the nuclei. Other stains can be used to identify other substances within the cell such as collagen, elastin, mucin, ferric iron, and other substances. Still other stains can be used to identify agents that infect the human

body such as bacteria and fungi. Many of the stains used to identify certain substances and/or structures within or outside the cell require the use of stains that are unstable, toxic, and generally messy and difficult to work with.

Presently, many automated and manual histochemical staining protocols 5 require the pre-mixing of two or more solutions prior to staining sample tissue. In many cases the mixing of several solutions to prepare a single solution for staining produces a staining solution that is inherently unstable. Instability may manifest itself by the appearance of precipitates or films in the staining solution. For example, many silver staining solutions are photolabile. Ammoniacal silver solutions 10 degrade rapidly and a silver residue can be observed on top of the solution within hours of mixing. The formation of films and precipitates negatively affects the staining of the tissue and therefore decrease the accuracy of histochemical testing. Furthermore, the daily preparation of fresh histochemical staining solutions is time 15 consuming. It may also be costly since expensive reagents such as silver nitrate may be squandered if staining solution is prepared and not used by the end of the day. Therefore, there exists a need for improved histochemical staining methods that employ unstable staining solutions.

The present invention obviates the need to prepare new staining preparations on a daily basis. The present invention permits the mixing of component 20 histochemical staining solutions on a sample tissue slide, solutions that have previously been combined in the laboratory prior to staining a slide sample. Unlike the combined solutions which are unstable, the separated component solutions are stable for long periods. The component histochemical solutions of the present invention may be stored as separate solutions for long duration and may then be

combined on sample tissue that has been placed on a microscope slide. The results of tissue assays using the component histochemical staining solutions of the present invention are equal to or better than manual or automated methods utilizing completely mixed standard histochemical staining solutions.

5

Summary of the Invention

The present invention relates to automated methods for staining biological materials on a slide comprising the use of component histochemical solutions combined directly on a biological sample of interest. In one embodiment, the method comprises providing at least two stable solutions that together comprise an unstable staining solution, sequentially delivering the stable solutions to a biological sample of interest on a planar surface, and combining the stable solutions directly on the biological material of interest to effectuate staining of the material. In specific 15 embodiments, methods are provided for automated silver staining, iron staining, trichrome staining, and mucicarmine staining.

In various preferred embodiments, the biological material is selected from the group consisting of tissue sections, tissue culture cells, nucleic acids, proteins, and chromosomes; the unstable staining solution is selected from the group 20 consisting of fungi staining solutions, silver staining solutions, trichrome staining solutions, mucin stains, mucicarmine staining solutions, iron staining solutions, Verhoff's staining solution, and Steiner staining solution, the solutions are mixed, and the mixing is accomplished by applying a gas stream to the at least first and second stable solutions on the biological material.

Detailed Description of the Preferred Embodiments

5 The present invention relates to automated methods for staining biological materials on a surface comprising the use of component histochemical solutions mixed directly on a biological sample of interest. There are many histochemical staining procedures that require the use of a staining solution that is made of several component solutions. These component solutions are mixed together prior to being
10 placed on a microscope slide containing a tissue section of interest. In the present invention these component solutions are kept in separate containers and only mixed after placement of each solution successively on the biological material of interest. In a preferred embodiment, the solutions are mixed on the slide by an automated histochemical instrument and the concentrations of the solutions optimized for the
15 instrument and the method of mixing. The methods of the present invention do not require mixing of the solutions, but such mixing speeds up and limits variation in the resulting solution.

As used herein, the term "solution" encompasses solutions, emulsions, and suspensions.

20 As used herein, the term "stable" means that the solution can be stored and re-used, and thus does not need to be made fresh prior to use. Preferably, a "stable solution" has a shelf-life of at least one week.

As used herein, the term "unstable" means that the solution exhibits diminished capacity to stain the target organism or tissue, upon standing for any
25 period of time, even as little as one hour. For example, many silver staining

solutions are photolabile and heat labile. Similarly, many staining solutions change color or form precipitates or films as a result of oxidation, such as iron hematoxylin, and must be discarded after use. The methods of the invention apply to any unstable multi-component staining solution that can be made by mixing two or more stable 5 sub-components together. Special stains color, or coat with metals, certain specific kinds of cells or cellular structures. This is done by applying, in sequence, dyes and other chemicals (oxidizers, reducing agents, metals) until the targeted staining is accomplished. Some stains employ as many as 10 different solutions. Each solution is termed a component of the stain.

10 Some individual components of the stain are made of "sub-components". If a final formulation of a solution cannot be stored until it is needed for use, then the separate ingredients must be made into "stock solutions" and combined immediately before use. The combined solution is not "stable", so it must be used within a short time, before it degrades and does not perform its function in the staining procedure.

15 This "unstable" combined solution is called a "working solution". A single component of a stain may have multiple sub-components that can be combined in a variety of ways to achieve the desired result.

20 The method of the present invention can be used with any histochemical solution that exhibits diminished capacity to stain the target organism or tissue, upon standing for any period of time, even as little as one hour. Such unstable multi-component staining solutions include, but are not limited to fungi staining solutions, silver staining solutions, iron staining solutions, iron hematoxylin solutions, trichrome staining solutions, mucin stains, mucicarmine staining solutions, Verhoff's staining solution, amyloid staining solutions, and Steiner staining solution.

See for example, Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology (McGraw-Hill, New York, Lee G. Luna, Ed. (1968)) (AFIP Manual); Theory and Practice of Histological Techniques (Churchill Livingston, NY, ed. by Bancroft and Stevens, 4th edition, 1996); both incorporated by reference 5 herein in their entirety. The method of the present invention can be used for bi-component, tri-component (as in the example above) and other multi-component unstable histochemical solutions.

For example, the conventional Grocott's method for fungi (GMS) requires a number of solutions to accomplish the staining of fungal tissue (chromic acid, 10 sodium bisulfite, gold chloride, sodium thiosulfate, light green solution). In addition, this staining protocol requires the use of a methanamine-silver nitrate-borax solution which is made by mixing a silver nitrate-methanamine stock solution (0.25% silver nitrate, 2.85% methanamine) with a 5% borax solution to produce a working methanamine-silver nitrate solution (0.125% silver nitrate, 1.425% 15 methanamine, 0.2% borax). While the stock methanamine-silver nitrate solution is stable, the working solution is unstable and thus must be made fresh every day.

In the present invention, the silver nitrate solution is kept separate from the methenamine-borax solution until the two solutions are mixed directly on the tissue of interest. In a preferred embodiment of the present invention the silver nitrate 20 solution is comprised of from about 0.2% to about 1.0% silver nitrate. In a preferred embodiment of the present invention the methenamine-borax solution is from about 2.0% to about 4.0% methenamine and from about 0.2% to about 0.6% borax in distilled water. In a preferred embodiment of the present invention the silver nitrate solution is added to the sample and after addition of a liquid coverslip solution, an

equal volume of methenamine-borax solution is added to the sample. Also, each of the three sub-components can be added as separate solutions to the sample. Furthermore, one of skill in the art will recognize that a methenamine-silver nitrate stock can be mixed on the tissue with the borax solution.

5 Similarly, conventional ammoniacal silver staining requires the use of both silver nitrate and ammonium hydroxide/sodium hydroxide solutions. While the stock silver nitrate and ammonium hydroxide/sodium hydroxide solutions are stable, the combined working solution is unstable and thus must be made fresh every day.

10 In the present invention, the silver nitrate solution is kept separate from the ammonium hydroxide/sodium hydroxide solution until the two solutions are mixed directly on the tissue of interest. In a preferred embodiment of the present invention the silver nitrate solution is comprised of from about 0.2 % to about 1.0 % silver nitrate. In a preferred embodiment of the present invention the ammonium hydroxide/sodium hydroxide solution is from about 0.3 % to about 1 % ammonium hydroxide and from about 0.1% to about 0.5% sodium hydroxide in distilled water. 15 Also, each of the three sub-components can be added as separate solutions to the sample.

20 Trichrome staining and mucicarmine staining require both Weigerts iron hematoxylin A and B solutions. While the stock Weigerts A and B solutions are stable, the combined working solution is unstable and thus must be made fresh every day.

 In the present invention, the Weigerts A solution is kept separate from the Weigerts B solution until the two solutions are mixed directly on the tissue of interest. In a preferred embodiment of the present invention the Weigerts A solution

is comprised of from about 0.7 % to about 1.5 % hematoxylin in 95% alcohol. In a preferred embodiment of the present invention the Weigerts B solution is from about 0.7% to about 1.5 % aqueous ferric chloride and from about 0.5 % to 1.5 % HCl in distilled water. In a preferred embodiment of the present invention the Weigerts B 5 solution is added to the sample and after addition of a liquid coverslip solution, an equal volume of Weigerts A solution is added to the sample.

Gomori's iron staining require both potassium ferrocyanate and hydrochloric acid solutions. While the stock solutions are stable, the combined working solution is unstable and thus must be made fresh every day.

10 In the present invention, the potassium ferrocyanate is kept separate from the hydrochloric acid solution until the two solutions are mixed directly on the tissue of interest. In a preferred embodiment of the present invention the potassium ferrocyanate solution is comprised of from about 8 % to about 12 % potassium ferrocyanate in 95% distilled water. In a preferred embodiment of the present 15 invention the hydrochloric acid solution is from about 15 % to about 30 % HCl in distilled water.

In the methods of the invention, the solutions can be contacted with the biological material for widely varying periods of timing to accomplish the object of staining the specimen. In one embodiment, the solution is contacted with the 20 biological specimen for between about one second and about one hour, preferably for between about 10 seconds and 45 minutes, and most preferably for between about one minute and 30 minutes.

The methods of the present invention can be performed over a wide temperature range. In one embodiment, the methods can be performed at between

about 20°C to about 90°C; more preferably at between about 40°C to about 70°C; and most preferably between about 50°C and about 60°C.

The parameters of temperature at which the staining is carried out, and the duration of contacting the biological specimen with the solution, can be varied 5 extensively depending upon the stain, the biological specimen, and the instrumentation used, as will be appreciated by one of skill in the art.

In a preferred embodiment of the present invention the solutions are added to the sample tissue by an automated mechanism which can mix the solutions on the slide. Such automated instruments include those described in U.S. Patent Nos. 10 5,595,707; 5,654,199; 5,654,200 and 5,650,327 herein incorporated by reference in their entirety. The particular concentrations of reagents in the component solutions can be optimized by standard experimental design to provide optimum ranges of concentrations, oxidation/reduction potentials, ionization, and/or pH.

In a preferred embodiment, the methods of the present invention are 15 automated. Manual and most robotic staining is performed by dipping the slides into open vessels that are filled with pre-mixed solutions of dyes and chemicals. A variant of this technique is flooding chambers containing the slides with the pre-mixed solutions. In contrast, in the method of the present invention, the slide or other surface is itself used as the container for the staining solution. The slides are 20 positioned flat, biological material side up, and aliquots of staining solutions are sequentially delivered and mixed on the biological material. Instrumentation for conducting such automated staining includes, but is not limited to the NexEs™ system (Ventana Medical Systems, Tuscon, AZ) and that disclosed in U.S. Patent

Nos. 5,654,200, 5,650,327, 5,654,199, and 5,595,707, all hereby incorporated by reference in their entirety.

In a preferred embodiment, methods are used to apply a layer over the "pool" of staining solution to prevent evaporation, regulate temperature, and enhance 5 mixing, such as that described in U.S. Patent Nos. 5,654,200, 5,650,327, 5,654,199, and 5,595,707, all hereby incorporated by reference in their entirety. In a particularly preferred embodiment, the layering method comprises (a) covering the sample with an aqueous surface layer by applying an aqueous solution to a planar surface adjacent a biological sample mounted thereon; and (b) covering the aqueous 10 surface layer with an evaporation inhibiting liquid layer by applying the evaporation inhibiting liquid to the planar support surface adjacent the biological sample in an amount sufficient to form a continuous layer of evaporation inhibiting liquid over the sample. The evaporation inhibiting liquid is substantially water-insoluble, substantially water-immiscible and substantially non-viscous; has a specific gravity 15 less than water, and a boiling point above 50° C.; and is devoid of chemical characteristics which would significantly interfere with biochemical reactions carried out on the sample. The biological sample can then be optionally treated (c) with an aqueous reagent solution by applying the reagent solution to the planar support surface adjacent the biological sample. The reagent solution flows to the 20 biological sample under the evaporation inhibiting liquid layer, and the sample is continuously protected from dehydration by the evaporation inhibiting layer.

The methods of the present invention include mixing the stable solutions on the surface of the biological sample. In a preferred embodiment, this is accomplished by applying at least one gas stream to an area of the surface of the

evaporation inhibiting liquid layer between the center of the evaporation inhibiting layer and the edge of the planar support surface, the gas stream having a central axis forming an acute angle with the planar support surface. According to one embodiment of the present invention, the reagent solution is preferably stirred by a 5 vortex formed by applying two off-center gas streams, flowing in opposite directions, to the surface of the evaporation inhibiting liquid layer. According to a further embodiment of the present invention, the stable solutions are stirred by a vortex formed by applying a single gas stream along a longitudinal edge of the slide, the gas stream originating from the distal edge of the slide.

10 Biological materials that can be stained by the methods of the invention include, but are not limited to tissue sections, tissue culture cells, cell components, including cell organelles, chromosomes, nucleic acids, carbohydrates, lipids, and proteins, smears of blood, sputum, and other body fluids, excretions and secretions, and micro-organisms including parasites, viruses, bacteria, and fungi.

15 The methods of the present invention can also utilize newly developed stains.

A generic method for applying the subject invention to most any stain comprises:

1. Reviewing the staining literature and selecting a particular staining protocol.
2. Evaluate the instrument platform to be used to determine parameters and limitations in time, temperature and rinsing and mixing events available on the instrument.
3. Adapt the staining procedure to conform to the instrument parameters.
Example: If more or less time is needed, but not available, then increase or decrease, temperature or reagent concentration.
4. Test the modified staining procedure and evaluate the result.
5. If the result is sub-optimal, then identify the component responsible for the problem.
6. Substitute or reformulate the reagent to compensate for the problem.
7. Retest and reevaluate in a loop until stain is optimized.

30

This procedure will permit one of skill in the art to apply the subject invention to most any staining procedure, including those described in *Theory and Practice of Histotechnology*, Dezna C Sheehan H.T (ASCP), Battelle Press, 2nd ed., 1980; and *Laboratory Histopathology*, Anthony E. Woods & Roy C. Ellis, Churchill Livingstone, 1st ed., 1994; both incorporated by reference herein in their entirety.

The following Examples are presented for illustrative purposes only and are not intended, nor should they be construed as limiting the invention in any way. Those skilled in the art will recognize that variations on the following can be made without exceeding the spirit or scope of the invention.

10

Example 1
Grocott's Method for Fungi (GMS) Staining

A solution of 0.35% silver nitrate was made by adding 0.35g silver nitrate to 15 100 ml de-ionized water. A solution of 3.0% methenamine and 0.4% borax was made by dissolving 3g methenamine and 0.4g of borax in 100 ml of distilled water. A solution containing 0.5% sodium bisulfite was made by dissolving 0.5g of sodium bisulfite in 100 ml of distilled water. A solution containing 3.75% chromic acid was made by dissolving 3.75g of chromium trioxide in 100 ml of distilled water. A 20 solution containing 0.2% gold chloride was made by dissolving 0.2g of gold chloride in 100 ml of distilled water. A solution containing 2.0% sodium thiosulfate was made by dissolving 2.0g of sodium thiosulfate in 100 ml of distilled water. A 0.05% light green solution was made by diluting 25 ml of stock solution (2g of light green dissolved in 99 ml distilled water and 1 ml glacial acetic acid) in 100 ml of de-ionized water. 200 μ l of the silver nitrate solution and 200 μ l of the methenamine-borax solution were dispensed onto a tissue sample mounted on a microscope slide

using an automated histochemical dispensing apparatus (Ventana Medical Systems, Inc., Tucson Arizona). The sample tissue, *Aspergillus ctyptococcus* was prepared for staining by standard technique. The sample tissue was place in the automated histochemical staining instrument and the following protocol was used in staining 5 the tissue.

In this example, as well as the four succeeding examples, the wash solution was comprised of 0.2% Tween 20 in de-ionized water (pH to 7.0 ± 0.5). Liquid coverslip is 99.99% Norpar 15 and less than 0.01% oil red 0.

10

TABLE 1

1. Warm-up rinse buffer to 41.0° C
2. Rinse slide
3. Adjust slide volume
4. Apply liquid coverslip
5. Warm slide chamber to 60.0° C
6. Rinse slide
7. Adjust slide volume
8. Apply liquid coverslip
9. Start timed steps
10. Rinse slide
11. Adjust slide volume
12. Apply 200µl of 4% chromic acid and incubate for 15 minutes
13. Apply liquid coverslip
14. Rinse slide
15. Adjust slide volume
16. Apply 200µl of 0.5% sodium bisulfite and incubate for 3 minutes
17. Apply liquid coverslip
18. Rinse slide
19. Rinse slide
20. Adjust slide volume
21. Apply 200 µl of 0.5% silver nitrate solution and incubate for 3 minutes
22. Apply liquid coverslip
23. Apply 200 µl of 4% methanamine/0.4% borax solution and incubate for 18 minutes
24. Apply liquid coverslip
25. Rinse slide
26. Adjust slide volume

27. Apply liquid coverslip
28. Apply 200 μ l of 0.2% gold chloride and incubate for 3 minutes
29. Apply liquid coverslip
30. Rinse slide
- 5 31. Adjust slide volume
32. Apply 200 μ l of 2.5% sodium thiosulfate solution and incubate for 3 minutes
33. Apply liquid coverslip
34. Rinse slide
- 10 35. Adjust slide volume
36. Apply liquid coverslip
37. Apply 200 μ l of light green solution and incubate for 3 minutes
38. Apply liquid coverslip
39. Rinse slide

15 A visual comparison between the tissue prepared using the automated protocol as described above was compared with the manual staining of identical tissue carried out in accordance with the protocol for GMS described in the Manual of Histologic Staining Methods of the Armed Forces Institute of Pathology
20 (McGraw-Hill, New York, Lee G. Luna, Ed. (1968)) (AFIP Manual). Such comparison showed that the tissue stained with the component solutions on the automated system were cleaner, *i.e.* no black ring around the sample tissue. All tissue samples remained attached to the slide, whereas those stained manually started to lift off the slide. The staining contrast was better on the slides stained with
25 the component solutions.

30 The silver nitrate solution and methanamine/borax solutions were stored at 4° C for three months, after which time the protocol in table 1 was re-run on similar tissue. A visual comparison was made between the tissue prepared as described above using the stored solutions and the manual staining of identical tissue with freshly made solutions. The staining comparison demonstrated that the tissue

stained by the stored solutions run on the automated system were comparable or better than tissue stained manually with freshly made solutions.

5

Example 2
Ammoniacal Silver Staining

A 10% silver nitrate stock solution was made by dissolving 10g of silver nitrate in de-ionized water. A working solution of 0.2% silver nitrate was made by diluting 2 ml of 10% stock solution with 48 ml of de-ionized water. An ammonium hydroxide/sodium hydroxide solution was made by dissolving 9.20 ml of 1N ammonium hydroxide and 3.60 ml of a 3% sodium hydroxide in 37.2 ml of de-ionized water. A solution containing 0.5% potassium permanganate was made by dissolving 0.5g of potassium permanganate in 100ml of distilled water. A solution containing 0.5% oxalic acid was made by dissolving 0.5g of oxalic acid in 100ml of distilled water. A solution containing 2.5% ferric ammonium sulfate was made by dissolving 2.5g of ferric ammonium sulfate in 100ml of distilled water. A solution containing 10% formalin was made by diluting 10 ml of concentrated formaldehyde (37-40%) in 90 ml distilled water. A solution of 0.2% gold chloride was made by dissolving 0.2g of gold chloride in 100ml of distilled water. A solution containing 2.0% sodium thiosulfate was made by dissolving 2g of sodium thiosulfate in 100 ml of distilled water. A solution of 1.5g/L nuclear fast red was made by dissolving 0.15g of nuclear fast red in 5% solution of aluminum sulfate (5g of aluminum sulfate in 100 ml distilled water) over heat. 200 μ l of 0.2% silver nitrate and 200 μ l of the ammonium hydroxide/sodium hydroxide solution were dispensed onto a tissue sample mounted on a microscope slide using an automated histochemical dispensing

apparatus (Ventana Medical Systems, Inc., Tucson Arizona). Sample liver tissue was prepared according to standard protocol. The sample tissue was placed in the automated histochemical staining instrument and the following protocol was used to stain the tissue.

5

TABLE 2

1. Warm-up rinse buffer to 41.0° C
2. Rinse slide
3. Adjust slide volume
4. Apply liquid coverslip
5. Warm slide chamber to 60.0° C
6. Rinse slide
7. Adjust slide volume
8. Apply liquid coverslip
9. Rinse slide
10. Adjust slide volume
11. Apply 200 μ l of 0.5% potassium permanganate and incubate for 3 minutes
12. Apply liquid coverslip
13. Rinse slide
14. Adjust slide volume
15. Apply 200 μ l of 0.15% oxalic acid and incubate for 3 minutes
16. Apply liquid coverslip
17. Rinse slide
18. Adjust slide volume
19. Apply 200 μ l of 2.5% ferric ammonium sulfate solution and incubate for 3 minutes
20. Apply liquid coverslip
21. Rinse slide
22. Apply 200 μ l of 0.2% silver nitrate solution and incubate for 3 minutes
23. Apply 200 μ l of ammonium hydroxide/sodium hydroxide solution and incubate for 3 minutes
24. Apply liquid coverslip
25. Rinse slide
26. Rinse slide
27. Adjust slide volume
28. Apply 200 μ l of 10% formalin solution and incubate for 3 minutes
29. Apply liquid coverslip
30. Rinse slide
31. Adjust slide volume
32. Apply 200 μ l of 0.2% gold chloride and incubate for 3 minutes
33. Apply liquid coverslip

34. Rinse slide
35. Adjust slide volume
36. Apply 200 μ l of 2.0% sodium thiosulfate and incubate for 3 minutes
37. Apply liquid coverslip
38. Rinse slide
39. Adjust slide volume
40. Apply 200 μ l of 1.5 g/L nuclear fast red and incubate for 3 minutes
41. Apply liquid coverslip
42. Rinse slide

10

A visual comparison between the tissue prepared as described above was compared with the manual staining of identical tissue carried out in accordance with the protocol for reticulum stain described in the AFIP Manual. Tissue stained by both techniques appeared to be identical.

15

The silver nitrate solution and ammonium hydroxide/sodium hydroxide solutions were stored at 4° C for two months, after which time the protocol in table 1 was re-run on similar tissue. A visual comparison between the tissue prepared as described above using the stored solutions was compared with manual staining of identical tissue with freshly made solutions carried out in accordance with the protocol for reticulum stain described in the AFIP Manual. The staining comparison demonstrated that the tissue stained by stored solutions run on the automated system were comparable or better than tissue stained manually with freshly made solutions.

20

A visual comparison between the tissue prepared as described above using the stored solutions was compared with manual staining of identical tissue with one day old solutions carried out in accordance with the protocol for reticulum stain described in the AFIP manual. The staining comparison demonstrated that the tissue stained by stored solutions run on the automated system was significantly better than tissue stained manually with the one day old solutions.

Example 3 *Masson's Trichrome Stain*

5

Solutions for Masson's Trichrome stain were made as follows. Weigert's iron hematoxylin solution A was made by adding 1g of hematoxylin to 100 ml of 95% alcohol. Weigert's iron hematoxylin solution B was made by adding 4 ml of 29% aqueous ferric chloride, 95 ml of distilled water and 1 ml hydrochloric acid together. Biebrich's scarlet-acid fuchsin solution was made by combining 90 ml of 5% aqueous solution of Biebrich's scarlet with 10 ml of 10% aqueous acid fuchsin and 1 ml glacial acid. The resultant solution was mixed and filtered through a Whatman 3 filter paper.

The 1% phosphotungstic acid solution was made by combining 1g phosphotungstic acid in 100 ml of de-ionized water. The aniline blue solution was made by adding 0.4g aniline blue to 100 ml of distilled water and 1ml of acetic acid. The acetic acid solution was made by adding 0.5ml acetic acid to 100 ml of distilled water.

Table 3

20 1. Warm-up rinse buffer to 41.0° C
2. Rinse slide
3. Warm slide chamber to 60.0° C
4. Rinse slide
25 5. Apply 300 µl of Weigerts B solution (1x) and incubate for 3 minutes
6. Apply liquid coverslip
7. Apply 200 µl of Weigerts A solution (1x) and incubate for 6 minutes
8. Apply liquid coverslip
9. Rinse slide
30 10. Rinse slide
11. Apply 200 µl of 5% Biebrich Scarlet solution and incubate for 9 minutes

12. Apply liquid coverslip
13. Rinse slide
14. Apply 300 μ l of 1% phosphotungstic acid solution and incubate for 6 minutes
- 5 15. Apply liquid coverslip
16. Rinse slide
17. Apply 200 μ l of 0.40% aniline blue and incubate for 3 minutes
18. Apply liquid coverslip
19. Rinse slide
- 10 20. Apply 300 μ l of 0.5% acetic acid and incubate for 3 minutes

A visual comparison between the tissue prepared as described above was compared with the manual staining of identical tissue carried out in accordance with the protocol for Masson's trichrome stain described in the AFIP Manual. The staining comparison demonstrated that the tissue stained by stored solutions when run on the automated system was comparable to tissue stained manually with freshly made solutions.

20 **Example 4**
Mucicarmine Staining

Solutions for mucicarmine staining were made as follows. Mayer's stock mucicarmine solution was made by combining 1g carmine and 0.5g anhydrous aluminum chloride in a Pyrex beaker and adding 2 ml distilled water. The solution was heated over a small flame and agitated with a glass rod for approximately 2 minutes until the solution turned purple and had the consistency of syrup. Thereafter, 100 ml of 50% ethanol was added to the syrupy mixture and the solution was incubated at room temperature for 24 h. The solution was filtered through Whatman 3 filter paper.

30

TABLE 4

1. Warm-up rinse buffer to 41.0° C
2. Rinse slide
3. Adjust slide volume
4. Apply liquid coverslip
5. Warm slide chamber to 60.0° C
6. Rinse slide
7. Adjust slide volume
8. Apply liquid coverslip
9. Start timed steps
10. Rinse slide
11. Adjust slide volume
12. Apply 300 µl of Weigerts B solution and incubate for 3 minutes
13. Apply 200 µl of Weigerts A solution and incubate for 3 minutes
14. Apply liquid coverslip
15. Rinse slide
16. Adjust slide volume
17. Apply 200 µl of mucicarmine solution and incubate for 6 minutes
18. Apply liquid coverslip
19. Rinse slide
20. Adjust slide volume
21. Apply liquid coverslip
22. Apply 100 µl of 0.1% tartrazine solution and incubate for 3 minutes
23. Apply liquid coverslip
24. Rinse slide

25. A visual comparison between the tissue prepared as described above was compared with the manual staining of identical tissue carried out in accordance with the protocol for mucicarmine stain described in the AFIP Manual. Tissue stained by both techniques appeared to be identical.

30

Example 5
Gomori's Iron Stain

35. A solution of 1.5g/L nuclear fast red was made by dissolving 0.15g of nuclear fast red in 5% solution of aluminum sulfate over heat. A solution of 20% hydrochloric acid was made by adding 20 ml concentrated hydrochloric acid with 80 ml distilled water. A 10% solution of potassium ferrocyanide was made by dissolving 10g potassium ferrocyanide in 100 ml distilled water.

TABLE 5

1. Warm-up rinse buffer to 41.0° C
2. Rinse slide
5. Adjust slide volume
3. Apply liquid coverslip
4. Warm slide chamber to 60.0° C
6. Rinse slide
7. Adjust slide volume
10. Apply liquid coverslip
8. Start timed steps
10. Rinse slide
11. Adjust slide volume
12. Apply 200 μ l 10% potassium ferrocyanate
15. Apply 200 μ l of 20.0% hydrochloric acid and incubate for 9 minutes
14. Apply liquid coverslip
15. Rinse slide
16. Adjust slide volume
17. Apply 100 μ l of 1.5% Nuclear fast red solution and incubate for 3 minutes
20. Apply liquid coverslip
18. Rinse slide
19. Rinse slide

A visual comparison between the tissue prepared as described above was
25 compared with the manual staining of identical tissue carried out in accordance with
the protocol for Gomori's iron stain described in the AFIP Manual. Tissue stained
by both techniques appeared to be identical.

The present invention is not limited by the aforementioned particular
preferred embodiments. It will occur to those ordinarily skilled in the art that
30 various modifications may be made to the disclosed preferred embodiments without
diverting from the concept of the invention. All such modifications are intended to
be within the scope of the present invention.